News Column

Researchers from Hospital for Special Surgery Report Findings in Clinical Trials and Studies

March 3, 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- Research findings on Clinical Research are discussed in a new report. According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "Analysis of data collected prospectively from the United States Food and Drug Administration Investigational Device Exemption (US FDA IDE) clinical trial for patients who underwent ProDisc-L arthroplasty at 1- and 2-levels performed at 2 study centers. To determine if there is any clinical or radiographical differences between patients who received 1-level ProDisc-L and patients who received 2-level ProDisc-L with a minimum follow-up of 5 years."

Our news editors obtained a quote from the research from Hospital for Special Surgery, "Summary of Background Data. Recent prospective US FDA clinical trial results have been published showing efficacy of the ProDisc (DePuy Synthes, West Chester, PA) prosthesis in both single and 2 level surgical procedures. Results of these prospective randomized multicenter FDA IDE clinical trials showed safety, efficacy, and superiority over circumferential fusion. Patients were part of the FDA clinical trial for the ProDisc-L versus circumferential fusion study at 2 institutions. We identified 20 patients who received ProDisc-L at 1 level and 21 who received it at 2 levels for a total of 41 patients. Pre- and postoperative pain, clinical function, and range of motion were measured. An unpaired t test was done to compare the 2-versus 1-level disc replacement patients. All patients had more than 60 months of clinical followup. The mean scores on the visual analogue scale were 37.1 and 28.7, respectively (P = 0.33) for 1- and 2-level patients. Oswestry Disability Index scores were 33 and 29.1, respectively for 1- and 2-level patients (P = 0.60); and SF-36 health survey physical scores were 43 and 43.9, respectively for 1- and 2-level patients (P = 0.81); SF-36 health survey mental scores were 46.2 and 46.6, respectively for 1- and 2-level patients (P = 0.923). The average final followup postoperative range of motion for 1- and 2-level total disc replacement was 6.0 degrees and 5.4 degrees, respectively (P = 0.632). This study was unable to identify statistical differences in all clinical and radiographical outcomes for patients who underwent 1- and 2-level ProDisc arthroplasty in a cohort from 2 centers."

According to the news editors, the research concluded: "Future studies with longer-term follow-up are needed to confirm these results."

For more information on this research see: A Comparison of Patients Who Have Undergone 1-Level Versus 2-Level Prodisc Arthroplasty A Prospective Study With Minimum of 5-Year Follow-up. SPINE, 2013;38(14):1194-1198. SPINE can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins -; SPINE -

The news editors report that additional information may be obtained by contacting J. Yue, Hospital for Special Surgery, Spine Care Inst, New York, NY 10021, United States. Additional authors for this research include K. Zhang, H.X. Bai, J. Du, F. Cammisa, C. Abjornson and F. Mo (see also Clinical Research).

Keywords for this news article include: Surgery, Arthroplasty, New York City, United States, Clinical Research, Orthopedic Procedures, North and Central America, Clinical Trials and Studies, Government Agencies Offices and Entities

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Pharma Business Week

Story Tools